The Global Health Body Raises Concern Over Acute Scarcity of Obesity Injections

Under 10% of patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, states the global health agency as it publishes its inaugural recommendations on the therapies.

Considering more than one billion people worldwide now living with obesity, it is urging more widespread and fairer access to these injectable treatments.

According to projections, over two billion could be obese by 2030 unless action is taken.

"The latest guidelines acknowledges that obesity is a chronic disease that can be addressed with thorough and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are key obstacles to widespread availability to the jabs that can help people shift considerable body mass, notes the body.

Skinny Jab Supply Crisis

Despite the current most favorable scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of eligible patients, per the WHO.

The advice encourages nations and manufacturers to expand access, by measures like patent sharing.

Exclusive production rights on the active ingredient – the primary component of a leading brand – is scheduled to end in several countries in 2026.

How Weight-Loss Jabs Operate

The injections replicate a body's own hormone to slow digestion, curb appetite and boost the sense of being full so users eat less.

People usually begin shedding pounds after several weeks of starting on the once-weekly jabs.

Research points to people may regain a significant portion after a year of stopping the treatment, as their normal appetite come back.

To be above a healthy weight increases your chance for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.

Obesity concerns individuals in every country and was associated with millions of fatalities worldwide in 2024, as per the health agency.